HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
The PERT Consortium shared a proud post on X:
”We’re excited to share enrollment for HI-PEITHO is now complete! With 544 patients enrolled across 72 sites in the United States in Europe, this landmark trial compares EKOS (Ultrasound Assisted Thrombolysis) with Anticoagulation vs Anticoagulation Alone in the treatment of intermediate-high risk PE patients. The study was a collaboration between The PERT Consortium, University Medical Center Mainz, and Boston Scientific. We extend our congratulations to all investigators and enrollment sites involved in this one-of-a-kind trial that will inform strategies for PE treatment around the world.”
Learn more abouth the HI-PEITHO here.
Enrollment for the HIPEITHO trial has successfully concluded, with 544 patients enrolled across 72 clinical sites in the United States and Europe.
In HIPEITHO Trial, the pivotal, multicenter study compares ultrasound-assisted catheter-directed thrombolysis using the EKOS system plus anticoagulation versus anticoagulation alone in patients with intermediate-high risk pulmonary embolism (PE).
A collaboration between The PERT Consortium, University Medical Center Mainz, and Boston Scientific, HIPEITHO trial represents a major step forward in evaluating treatment strategies for PE.
The results are expected to significantly inform clinical decision-making and global PE management.
Congratulations to all investigators and sites for their contribution to this groundbreaking trial!
Find the latest scientific advancements in thrombosis management featured in Hemostasis Today.
-
Sep 11, 2025, 08:33Alfonso J. Tafur Shares VascuLearn’s Free Virtual Support Groups This Fall for Patients and Providers
-
Sep 10, 2025, 23:00Blood Vessels, Thrombosis and Hemostasis - Blood VTH and Blood Neoplasia: Now Indexed in PubMed!
-
Sep 10, 2025, 13:00Shivani Modi Presents 7 Posters at SOHO 2025: From AI to Hematologic Emergencies
-
Sep 10, 2025, 09:27Deep Vein Thrombosis (DVT) Explained in One Slide: Causes, Symptoms, Diagnosis and Treatment
-
Sep 10, 2025, 09:20Giuseppe Biondi Zoccai Celebrates Release of New Book on Medical Statistics
-
Sep 10, 2025, 22:34Nicolas Gendron on The Emerging Role of CLIA in The Diagnosis Strategy for HIT
-
Sep 10, 2025, 21:13Gregory Piazza on The Link Between VTE and Atherothrombosis
-
Sep 10, 2025, 19:00Maria Meritxell Roca Mora: DOACs Show Promise Over VKAs in Kidney Transplant Recipients
-
Sep 10, 2025, 08:20Flora Peyvandi on Caplacizumab: Which VWF Assays Truly Measure Treatment Effectiveness?
-
Sep 10, 2025, 03:36International Journal of Stroke: Rising Incidence of Stroke in Young Adults
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 7, 2025, 14:13Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
-
Sep 11, 2025, 08:08Al-Ola A Abdallah on MGUS-Related Bleeding Disorders
-
Sep 10, 2025, 19:32Denis Brutus Oduor: Call for Altruism in Blood Donation in Nairobi
-
Sep 9, 2025, 10:34James Douketis Receives the 2025 Distinguished Service Award in General Internal Medicine!
-
Sep 9, 2025, 08:07Hemophilia Federation of America Launches ‘Blood Brothers’ Podcast for Men With Bleeding Disorders
-
Sep 9, 2025, 04:57World Thrombosis Day 2025: Louise Bannon Invites Donations and Partnerships